Related Experiment Video

Updated: Jun 23, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients

Monika Buraczynska1, Piotr Ksiazek, Pawel Zukowski

  • 1Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Lublin, Poland. monika.buraczynska@am.lublin.pl

Clinical Immunology (Orlando, Fla.)
|May 12, 2009
PubMed

Insights

The CFH Y402H gene variant is linked to cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD). This genetic factor significantly increases the risk of CVD in dialyzed individuals.

Area of Science:

  • Nephrology
  • Cardiology
  • Genetics

Background:

  • Cardiovascular disease (CVD) is the primary cause of mortality in end-stage renal disease (ESRD).
  • Complement factor H (CFH) is implicated in CVD risk, but its specific role in ESRD patients is unclear.

Purpose of the Study:

  • To investigate the association between the CFH Y402H polymorphism and CVD risk in a large cohort of ESRD patients.
  • To determine if CFH Y402H acts as an independent risk factor for cardiovascular comorbidity in dialyzed patients.

Main Methods:

  • Genotyping of the CFH Y402H (T1277C) polymorphism in 1200 ESRD patients and 818 healthy controls.
  • Comparison of genotype frequencies between ESRD patients with and without CVD, and with healthy controls.
  • Multivariate logistic regression analysis to assess independent associations.

Main Results:

  • Significant differences in genotype frequencies were observed between ESRD patients with CVD and those without, as well as healthy controls (p<0.001).
  • Homozygosity for the C allele of CFH Y402H was strongly associated with CVD in ESRD patients (OR=7.28, 95% CI 5.32-9.95).
  • No significant differences were found between ESRD patients without CVD and healthy controls.

Conclusions:

  • The CFH Y402H polymorphism is associated with an increased susceptibility to cardiovascular disease in patients undergoing dialysis.
  • This genetic variant represents an independent risk factor for cardiovascular comorbidity in the ESRD population.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...